Kris Todd
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Inflammatory Bowel Disease, Psoriasis: Treatment and Pathogenesis, Pregnancy and Medication Impact, Dermatology and Skin Diseases, Microscopic Colitis
Most-Cited Works
- → Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis(2018)118 cited
- Chronic Noncancer Pain Management and Systemic Racism: Time to Move Toward Equal Care Standards(2020)
- → Long-Term Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis: An Integrated 2-Year Safety Analysis(2025)1 cited
- → Safety and Pharmacokinetics of Single‐Dose Mirikizumab in Chinese Healthy Participants: Results From a Phase 1 Study(2024)1 cited
- Nursing care of AIDS patients participating in a Phase I/II trial of recombinant human granulocyte-macrophage colony stimulating factor.(1988)
- → S1108 Safety, Tolerability, and Pharmacokinetics of Mirikizumab in Chinese Healthy Subjects: Results From a Phase 1 Study(2023)
- → Ixekizumab efficacy and safety in moderate-to-severe genital psoriasis(2018)
- → Persistance de l’amélioration clinique du psoriasis génital après un an de traitement par ixékizumab : résultats d’une étude clinique de phase 3 randomisée contrôlée versus placebo chez des patients atteints de psoriasis génital modéré à sévère (IXORA-Q)(2019)
- → Su1800 EFFICACY AND SAFETY OF MIRIKIZUMAB THERAPY IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 2 SHINE-1 STUDY(2024)